Aptuit (Switzerland) AG / Exquiron

www.exquiron.com

Exquiron is dedicated to contract research in early stage drug discovery. Our services span from assay development and adaptation for hit finding and profiling purposes to compound selection, high throughput screening, selectivity testing and hit characterization, and SAR expansion. Our scientists will work with you to identify the most suitable approach to reach your program milestones as rapidly, efficiently and economically as possible.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

Q² SOLUTIONS LAUNCHES INNOVATIVE SELF-COLLECTION SAFETY LAB PANEL IN COLLABORATION WITH TASSO

Q² Solutions and IQVIA, Tasso | October 07, 2022

news image

Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory. Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-...

Read More

Medical

BOTANICAL SOLUTION INC. (BSI) SECURES $6.1 MILLION IN SERIES A FIRST CLOSING

Botanical Solution Inc. | January 18, 2022

news image

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. Read More

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

news image

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More

Medical

PACBIO TRANSFORMS ACCESS TO THE EPIGENOME AND STREAMLINES WORKFLOWS

PacBio | April 23, 2022

news image

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems. This extends PacBio’s unique and highly capable HiFi sequencing technology to now include access to the epigenome, a second layer of genomic information often left unexplored due to fundamental limitations of common sequencing technologies. PacBio’s single-mole...

Read More
news image

Cell and Gene Therapy

Q² SOLUTIONS LAUNCHES INNOVATIVE SELF-COLLECTION SAFETY LAB PANEL IN COLLABORATION WITH TASSO

Q² Solutions and IQVIA, Tasso | October 07, 2022

Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory. Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-...

Read More
news image

Medical

BOTANICAL SOLUTION INC. (BSI) SECURES $6.1 MILLION IN SERIES A FIRST CLOSING

Botanical Solution Inc. | January 18, 2022

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. Read More

news image

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More
news image

Medical

PACBIO TRANSFORMS ACCESS TO THE EPIGENOME AND STREAMLINES WORKFLOWS

PacBio | April 23, 2022

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems. This extends PacBio’s unique and highly capable HiFi sequencing technology to now include access to the epigenome, a second layer of genomic information often left unexplored due to fundamental limitations of common sequencing technologies. PacBio’s single-mole...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us